Drug intelligence / Profile preview

Qilong Dingchuan

Lead developer
Yiling Pharmaceutical
Administration
Oral
01

Overview

Qilong Dingchuan (also known as Qilong Dingchuan Tablets) is an oral traditional Chinese medicine (TCM) tablet developed by Shijiazhuang Yiling Pharmaceutical. Formulated under the guidance of the collateral disease (络病) theory, it is designed to replenish qi, activate blood circulation, dredge collaterals, resolve phlegm, relieve cough, and calm wheezing. Qilong Dingchuan is primarily developed for the treatment of stable chronic obstructive pulmonary disease (COPD) in patients presenting with heart-lung qi deficiency and phlegm-blood stasis syndrome. The drug is currently in Phase II clinical development in China.

Other names
Qilong Dingchuan Tablets芪龙定喘芪龙定喘片
02

Targets

Beyond the preview

Go deeper on Qilong Dingchuan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qilong Dingchuan.

Work on Qilong Dingchuan? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call